Patent Application
20230048601
This application relates generally to a treatment for Alzheimer's Disease, and, more particularly, to an extracorporeal radiofrequency methodology for the treatment of Alzheimer's Disease.
Alzheimer's Disease is a neurodegenerative disease that causes almost seventy percent of cases of dementia. This disease causes memory dysfunction, problems with language, psychiatric dysfunctions such as mood swings, loss of motivation, self-care neglect and behavioral issues. There are presently no treatments that reverse its progression. Cases of Alzheimer's Disease have been reported in all countries, where it has caused a great deal of morbidity and mortality. There is a need for treatments for Alzheimer's Disease, due to the worldwide burden of this disease.
In summary, one embodiment provides a method for treating a body fluid of a patient with Alzheimer's Disease, comprising: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an Alzheimer's targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a radiofrequency absorption enhancer; removing the antibody-TA complex from the body fluid using a radiofrequency source; and returning the body fluid to the patient.
Another embodiment provides a device for treating a body fluid of a patient with Alzheimer's Disease, comprising: a transparent first stage including an inlet for the body fluid and at least one exterior wall defining a treatment chamber; a transparent second stage, fluidly connected to the first stage, comprising a removal module and an outlet for the body fluid, wherein the treatment chamber comprises a delivery tube for introducing an antibody into the treatment chamber, wherein the delivery tube comprises a hollow tube including at least one interior wall defining a plurality of holes through which the antibody can be added to the treatment chamber, wherein the treatment is delivered through the hollow tube in counter-current mode with reference to the body fluid; and a radiofrequency source; the device being configured to: remove the body fluid from a patient; apply a treatment to the body fluid, wherein the treatment comprises the antibody that joins with a target antigen (TA) in the body fluid to form an antibody-Alzheimer's Disease targeted antigen (TA) complex, wherein the antibody comprises a radiofrequency absorption enhancer; remove the antibody-TA complex from the body fluid using the radiofrequency source; and return the body fluid to the patient.
A further embodiment provides a product for treating a body fluid of a patient with Alzheimer's Disease, comprising: a transparent first stage including an inlet for the body fluid and at least one exterior wall defining a treatment chamber; a transparent second stage, fluidly connected to the first stage, comprising a removal module and an outlet for the body fluid, wherein the treatment chamber comprises a delivery tube for introducing an antibody into the treatment chamber, wherein the delivery tube comprises a hollow tube including at least one interior wall defining a plurality of holes through which the antibody can be added to the treatment chamber, wherein the treatment is delivered through the hollow tube in counter-current mode with reference to the body fluid, wherein the treatment comprises an antibody that joins with an Alzheimer's targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a radiofrequency absorption enhancer; and a radiofrequency source.
The foregoing is a summary and thus may contain simplifications, generalizations, and omissions of detail; consequently, those skilled in the art will appreciate that the summary is illustrative only and is not intended to be in any way limiting.
For a better understanding of the embodiments, together with other and further features and advantages thereof, reference is made to the following description, taken in conjunction with the accompanying drawings. The scope of the invention will be pointed out in the appended claims.
It will be readily understood that the components of the embodiments, as generally described and illustrated in the figures herein, may be arranged and designed in a wide variety of different configurations in addition to the described example embodiments. Thus, the following more detailed description of the example embodiments, as represented in the figures, is not intended to limit the scope of the embodiments, as claimed, but is merely representative of example embodiments.
Reference throughout this specification to “one embodiment” or “an embodiment” (or the like) means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, appearances of the phrases “in one embodiment” or “in an embodiment” or the like in various places throughout this specification are not necessarily all referring to the same embodiment.
Furthermore, the described features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. In the following description, numerous specific details are provided to give a thorough understanding of embodiments. One skilled in the relevant art will recognize, however, that the various embodiments can be practiced without one or more of the specific details, or with other methods, components, materials, et cetera. In other instances, well-known structures, materials, or operations are not shown or described in detail. The following description is intended only by way of example, and simply illustrates certain example embodiments.
Alzheimer's Disease is present worldwide and become a global health care problem. The loss of life, suffering, and economic struggles have reached all corners of the globe. Alzheimer's Disease is a neurodegenerative disease that causes almost seventy percent of cases of dementia. This disease causes memory dysfunction, problems with language, psychiatric dysfunctions such as mood swings, loss of motivation, self-care neglect and behavioral issues. There are presently no treatments that reverse its progression. There is therefore a need for treatments to reduce Alzheimer's Disease symptomatology in a clinical setting.
Accordingly, a method for the extracorporeal treatment of a patient's body fluid, CSF (cerebrospinal fluid) and/or blood, with the utilization of radiofrequency technology for the eradication of the Alzheimer's Disease Target Antigens (TAs): β-amyloid peptide, (Aβ)/beta-amyloid peptide, Aβ residues 1-42 (Aβ1-42), amyloid precursor protein (APP), tau, phosphorylated tau (pThr181) (p-tau), α-synuclein (αSyn), Lewy neurites, γ-Secretase: and/or its components APH1, PEN2, nicastrin, and presenilin 1 (PSEN1), presenilin 2 (PSEN2), and acetylcholinesterase in the body fluid to form an antibody-TA complex, wherein the antibody comprises a tag sensitive to a radiofrequency; in said body fluid is described herein. Disclosed is a method for the extracorporeal treatment of a patient's body fluid with the utilization of radiofrequency for the eradication of Alzheimer's Disease target pathogenic antigen(s)/TPAs in the body fluid. Bodily fluid can be selected from a group consisting of cerebrospinal fluid (CSF) and blood, and combinations thereof. The treatment includes stages comprising removing the body fluid from a patient which contains Alzheimer's Disease target antigens, exposing and binding those target pathogenic antigen(s) to antibodies forming TA-antibody complexes, eradicating the antibody bound Targeted Pathogenic Antigen(s)/TPAs utilizing radiofrequency (RF), and then returning the body fluid to the patient.
The illustrated example embodiments will be best understood by reference to the figures. The following description is intended only by way of example, and simply illustrates certain example embodiments.
In an embodiment, method may treat a patient's body fluid extracorporeally with conjugated antibody(s) designed to react with and bind up particular targeted pathogenic antigen(s)/TPA(s) of Alzheimer's Disease that include, but are not limited to: β-amyloid peptide, (Aβ)/beta-amyloid peptide, Aβ residues 1-42 (Aβ1-42), amyloid precursor protein (APP), tau, phosphorylated tau (pThr181) (p-tau), α-synuclein (αSyn), Lewy neurites, γ-Secretase: and/or its components APH1, PEN2, nicastrin, and presenilin 1 (PSEN1), presenilin 2 (PSEN2), and acetylcholinesterase.
Short-duration emissive energy from a high energy radiation emissive source may then be used to eradicate the Alzheimer's Disease target pathogen antigen(s)-antibody complexes in the body fluid, and then returning the body fluid back to the patient.
In an embodiment, in a first stage, a body fluid is withdrawn from a patient using standard medical techniques. A convenient method for removing blood is by using the standard venipuncture technique. A convenient method for removing the CSF is by using the standard lumbar puncture technique. Other techniques known to those skilled in the art are contemplated by this disclosure.
In an embodiment, in a second stage a treatment is applied to a body fluid extracorporeally. The treatment comprises exposing the body fluid to a tagged antibody generated to bind specific targeted Alzheimer's Disease pathogenic antigens (TPAs) of Alzheimer's Disease such as those described above. During this treatment the conjugated antibody(s) and the targeted pathogen antigen form TPA-antibody complexes.
In an embodiment, a method for enhancing radiofrequency (RF) absorption may include providing targeted RF enhancers, such as antibodies with an attached RF absorption enhancer, such as, for example metal particles. The antibodies target and bind to the Alzheimer's Disease target pathogen antigen. Binding RF enhancing particles to the antibodies (and other carriers having at least one targeting moiety) permits the injection of the antibodies (and other carriers having at least one targeting moiety) into the extracorporeal target solution.
The RF enhancers may induce the absorption of energy in the antibody-RF enhancing moiety TA complex (ARFTAC). In addition, a combination of antibodies (and other carriers having at least one targeting moiety) bound to different metals (and other RF absorbing particles) can be used allowing for variations in the RF absorption characteristics in the extracorporeal target area.
In an embodiment, the energy of the emitted radio frequency (RF) annihilates the antibody-RF enhancing moiety-TA (target antigen) complex (ARFTAC), thereby destroying its disease-causing potential. The entire system may be monitored and controlled utilizing a computer, in real time, utilizing time units of 1 millisecond or less during the entire procedure. Persons having ordinary skill in art will recognize that the steps described above can be performed on various devices, machines, or systems. This disclosure contemplates all known devices, machines, or systems that can perform the steps described in the above illustrative example.
In an embodiment, the second stage substantially eliminates, through a high-energy radiofrequency emissive source targeting and annihilating, the antibody-RF enhancing moiety-TA complex (ARFTAC) in the body fluid.
In an embodiment, a method for killing the Covid-19 virus may be performed by introducing into the extracorporeal patient body fluid (blood or CSF) RF absorption enhancers capable of selectively binding to the target antigen(s) and further capable of generating sufficient heat to kill or damage the bound target antibody-TA complexes by heat generated solely by the application of an RF field generated by an RF signal between a transmission head and a reception head.
In an embodiment, to achieve the eradication of the Covid-19 virions, one may arrange for the transmission and reception heads on opposite sides of a portion of the extra-corporeal body fluid sample for treatment. Irradiating the portion of the extra-corporeal body fluid sample between the transmission and reception heads containing RF absorption enhancers with an RF field kills or damages the Alzheimer's Disease targeted antigen(s) from the heat generated by the RF absorption enhancers.
The body fluid, from which the Alzheimer's Disease targeted antigens have been eradicated, may then be returned to the patient, free of the disease-causing antigens. Persons having ordinary skill in art will recognize that the steps described above can be performed on various devices, machines, or systems. This disclosure contemplates all known devices, machines, or systems that can perform the steps described in the above illustrative example.
Referring to
Referring to
In an embodiment, as an alternative to using a type of device as described above, the Alzheimer's Disease targeted antigens: β-amyloid peptide, (Aβ)/beta-amyloid peptide, Aβ residues 1-42 (Aβ1-42), amyloid precursor protein (APP), tau, phosphorylated tau (pThr181) (p-tau), α-synuclein (αSyn), Lewy neurites, γ-Secretase: and/or its components APH1, PEN2, nicastrin, and presenilin 1 (PSEN1), presenilin 2 (PSEN2), and acetylcholinesterase may be captured using antibody microarrays containing antibody-RF enhancing moieties in microarrays. An antibody microarray is a protein microarray; a collection of capture antibodies is fixed on a solid surface, such as glass, plastic, and silicon chip for the purpose of detecting antigens. Antibody microarrays may be composed of millions of identical monoclonal antibodies attached at high density on glass or plastic slides, all of which are transparent. Any microarrays known by those skilled in the art sufficient to perform the described technique are contemplated by this disclosure.
In an embodiment, there may be an extracorporeal exposure of the Targeted Antigens/TAs: β-amyloid peptide (Aβ)/beta-amyloid peptide, Aβ residues 1-42 (Aβ1-42), amyloid precursor protein (APP), tau, phosphorylated tau (pThr181) (p-tau), α-synuclein (αSyn), Lewy neurites, γSecretase: and/or its components APH1, PEN2, nicastrin, and presenilin 1 (PSEN1), presenilin 2 (PSEN2), and acetylcholinesterase. This may create an antibody pathogen complex on the microarray. The complexes are then tracked using an appropriate sensor and obliterated using a high energy focused emissive energy by the methodology of Kanzius. Steps in the process may be monitored and controlled by a computer in real time. Persons having ordinary skill in art will recognize that the steps described above can be performed on various devices, machines, or systems. This disclosure contemplates all known devices, machines, or systems that can perform the steps described in the above illustrative example.
In an embodiment, to eradicate the targeted antigens-antibody complexes after exposure in the microarrays, the body fluid may then be forced through a container constructed from a transparent material such as glass, or other material, which exposes the antibody-RF enhancing moiety-TA complex (ARFTAC) to a sensing device. The sensing device also creates an enlarged, magnified visual image of the antibody-RF enhancing moiety-virion complex (ARFVC). A concentrated and focused intense energy beam, such as light, may be used to properly illuminate and would use optical pattern recognition of the antibody-RF enhancing moiety-virion complex (ARFVC). Persons having ordinary skill in art will recognize that the steps described above can be performed on various devices, machines, or systems. This disclosure contemplates all known devices, machines, or systems that can perform the steps described in the above illustrative example.
The temperature of the treated body fluid may be maintained at 98.6° F. via continuous cooling of the body fluid using a standard cooling apparatus. A constant thermostatic measurement and control system continuously monitors the process to maintain the body fluid temperature at 98.6° F. Persons having ordinary skill in art will recognize that the steps described above can be performed on various devices, machines, or systems. This disclosure contemplates all known devices, machines, or systems that can perform the steps described in the above illustrative example.
In an embodiment, the Alzheimer's Disease target antigen(s)/TA(s): β-amyloid peptide (Aβ)/beta-amyloid peptide, Aβ residues 1-42 (Aβ1-42), amyloid precursor protein (APP), tau, phosphorylated tau (pThr181) (p-tau), α-synuclein (αSyn), Lewy neurites, γ-Secretase: and/or its components APH1, PEN2, nicastrin, and presenilin 1 (PSEN1), presenilin 2 (PSEN2), and acetylcholinesterase may be identified and differentiated using standard ELISA methodology. Identification can be done before treatment to determine which TAs, and their concentrations, are present in a patient's CSF and/or blood, and after treatment to analyze the efficiency of removal of the TA. ELISA (enzyme-linked immunosorbent assay) is a biochemical technique which allows for the detection of an antigen in a sample. In ELISA an antigen may be affixed to a surface, and then an antibody is utilized for binding to the antigen. The antibody is linked to an enzyme which enables a color change in the substrate. Other strategies may be employed to validate the level of target antigen(s)/TA(s) in the body fluid before or after treatment: Western blotting technology, UV Nis spectroscopy, mass spectrometry, and surface plasmon resonance (SPR). Another alternative methodology would utilize a molecular weight cut-off filtration. Molecular weight cut-off filtration refers to the molecular weight at which at least 80% of the target antigen(s)/TA(s) is prohibited from membrane diffusion.
In an embodiment, a portion of the purified body fluid may be tested to ensure that an acceptable portion of the Alzheimer's Disease targeted antigen(s)/TA(s) has been successfully removed from the body fluid using methods discussed throughout this application. Testing can determine the length of treatment and evaluate the efficacy of the eradication methodology in removing the targeted antigens. Body fluid with an unacceptably high concentration of Alzheimer's Disease target antigen(s)-antibody complexes remaining can then be re-treated before returning the body fluid to the patient.
The treatment may eradicate the targeted Alzheimer's Disease antigen(s) and subsequently the targeted antigens from the body fluid. The cleansed body fluid may then be returned to the patient, for example by using the same catheter that was originally used in removing the body fluid. In one non-limiting embodiment, the treatment of CSF comprises removing 5 ml to 40 ml (milliliters) of CSF from a patient, and then applying the treatment to the CSF before returning it to the patient. The frequency of such treatments would depend upon an analysis of the underlying symptomatology and pathology of the patient.
Referring to
Referring to
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.”
Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
While the invention has been particularly shown and described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.
Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims.
It can be appreciated from the foregoing that electronic components of one or more systems or devices may include, but are not limited to, at least one processing unit, a memory, and a communication bus or communication means that couples various components including the memory to the processing unit(s). A system or device may include or have access to a variety of device readable media. System memory may include device readable storage media in the form of volatile and/or nonvolatile memory such as read only memory (ROM) and/or random access memory (RAM). By way of example, and not limitation, system memory may also include an operating system, application programs, other program modules, and program data.
Embodiments may be implemented as an instrument, system, method or program product. Accordingly, an embodiment may take the form of an entirely hardware embodiment, or an embodiment including software (including firmware, resident software, micro-code, etc.) that may all generally be referred to herein as a “circuit,” “module” or “system.” Furthermore, embodiments may take the form of a program product embodied in at least one device readable medium having device readable program code embodied thereon.
A combination of device readable storage medium(s) may be utilized. In the context of this document, a device readable storage medium (“storage medium”) may be any tangible, non-signal medium that can contain or store a program comprised of program code configured for use by or in connection with an instruction execution system, apparatus, or device. For the purpose of this disclosure, a storage medium or device is to be construed as non-transitory, i.e., not inclusive of signals or propagating media.
Program code for carrying out operations may be written in any combination of one or more programming languages. The program code may execute entirely on a single device, partly on a single device, as a stand-alone software package, partly on single device and partly on another device, or entirely on the other device. In some cases, the devices may be connected through any type of connection or network, including a local area network (LAN) or a wide area network (WAN), or the connection may be made through other devices (for example, through the Internet using an Internet Service Provider), through wireless connections, e.g., near-field communication, or through a hard wire connection, such as over a USB connection.
Example embodiments are described herein with reference to the figures, which illustrate example methods, devices and products according to various example embodiments. It will be understood that the actions and functionality may be implemented at least in part by program instructions. These program instructions may be provided to a processor of a device, e.g., a hand-held measurement device, or other programmable data processing device to produce a machine, such that the instructions, which execute via a processor of the device, implement the functions/acts specified.
It is noted that the values provided herein are to be construed to include equivalent values as indicated by use of the term “about.” The equivalent values will be evident to those having ordinary skill in the art, but at the least include values obtained by ordinary rounding of the last significant digit.
This disclosure has been presented for purposes of illustration and description but is not intended to be exhaustive or limiting. Many modifications and variations will be apparent to those of ordinary skill in the art. The example embodiments were chosen and described in order to explain principles and practical application, and to enable others of ordinary skill in the art to understand the disclosure for various embodiments with various modifications as are suited to the particular use contemplated.
Thus, although illustrative example embodiments have been described herein with reference to the accompanying figures, it is to be understood that this description is not limiting and that various other changes and modifications may be affected therein by one skilled in the art without departing from the scope or spirit of the disclosure.
This application claims priority to U.S. Provisional Patent Application Ser. No. 63/231,986, filed on Aug. 11, 2021, and entitled “TREATING ALZHEIMER'S DISEASE. UTILIZING EXTRACORPOREAL RADIOFREQUENCY,” the contents of which are incorporated by reference herein.
| Number | Date | Country | |
|---|---|---|---|
| 63231986 | Aug 2021 | US |
